Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products through a direct selling channel in multiple international markets. The company’s core business consists of two primary product categories: beauty products, including skincare, cosmetics, and devices, and wellness products, primarily nutritional supplements. Key brands include Nu Skin, Pharmanex, Nutricentials, Beauty Focus, and ageLOC, which features anti-aging solutions across both categories. The company manufactures connected beauty and wellness devices, such as the ageLOC LumiSpa iO, ageLOC WellSpa iO, Nu Skin RenuSpa iO, and the data-enabled Prysm iO, which integrate with mobile applications to provide personalized insights. Nu Skin also operates Rhyz Inc., a strategic investment arm formed in 2018 that holds consumer, technology, and manufacturing companies to optimize supply chains and diversify revenue. The company was founded in 1984 and maintains research and development facilities in the United States and Mainland China, collaborating with academic institutions globally.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Household & Personal Products Homepage nuskin.com
Sector Consumer Defensive IR page ir.nuskin.com
Tags
direct selling, beauty devices, nutritional supplements, anti-aging skincare, connected devices, personal care, wellness products, cosmetics, Nu Skin, Pharmanex, ageLOC, Nutricentials, Beauty Focus, ageLOC LumiSpa iO, ageLOC WellSpa iO, Nu Skin RenuSpa iO, Prysm iO, ageLOC TruFace, ageLOC TRME, LifePak, Rhyz Inc., Nu Skin Vera, Nu Skin Stela, Nu Skin Facial Spa System
Press page —

Metrics

Valuation  
Market cap $ 220.512M
Market cap (USD) $ 220.512M
P/E -0.93
PEG —
P/BV 0.40
P/S 0.17
P/OCF 14.50
P/FCF -8.40
Dividend yield 0.44%
Turnover / mcap —
Returns  
ROE 22.0%
ROI 15.6%
ROIC 5.2%
Profit margin 10.8%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 15.2%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 37.2%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 7
Quality score 10.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 1.485B 1.732B 1.969B 2.226B 2.696B 2.582B 2.42B 2.679B 2.279B 2.208B — — 3.177B 2.17B 1.744B 1.537B 1.331B 1.248B 1.158B 1.115B 1.181B 1.138B 986.457M 964.067M 885.621M 879.758M
Net profit 160.204M -146.594M 8.595M 104.778M 147.266M 191.355M 173.553M 121.887M 129.437M 143.086M 133.046M 189.176M 364.888M 221.645M 153.33M 136.051M 89.845M 65.347M 43.872M 32.817M 74.033M 77.674M 67.876M 64.843M 50.313M 61.7M
Free cash flow 46.009M 70.159M 60.149M 49.006M 72.967M 315.318M 111.864M 132.367M 242.399M 225.042M 265.487M -157.94M 345.073M 214.331M 182.506M 134.1M 113.729M 87.3M 25.917M 40.115M 83.216M 95.354M 85.508M 92.09M 59.291M 20.358M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 9.62 6.89 19.42 42.16 50.75 54.63 40.98 61.33 68.23 47.78 37.89 43.7 138.22 37.03 48.57 30.13 26.85 10.39 17.32 18.63 — — — — — —
Price performance 12m 0.4 -0.65 -0.54 -0.17 -0.07 0.33 -0.33 -0.1 0.43 0.26 -0.13 -0.68 2.73 -0.24 0.61 0.12 1.58 -0.4 -0.07 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — 50.4M 63.4M 41.3M 47.4M 72.9M 50.8M 39.5M
↳ YoY growth +25.8% -34.8% +14.7% +53.9% -30.3% -22.1%
↳ 5y CAGR +0.2% -9.0%
Borrowings, current (USD) 82.7M 77.8M 69.5M 27.5M 30M 108M 25M 25M 30M 20M
Borrowings, non-current (USD) 334M 311M 361M 334M 305M 269M 377M 478M 364M 204M
Lease liabilities (USD) — — 0.00 145M 165M 128M 118M 104M 84.6M 82.4M
Cash and deposits (USD) 357M 426M 387M 336M 403M 340M 265M 256M 187M 239M
Intangible assets (USD) 63.6M 67.6M 90M 80.3M 89.5M 77M 66.7M 105M 74.3M 42.6M
Right-of-use assets (USD) — — 0.00 144M 155M 121M 98.7M 90.1M 72.6M 74M
Net debt (borrowings + leases - cash) (USD) 59.6M -37.8M 43.6M 171M 97.7M 164M 256M 351M 291M 68M
Cash flow detail
Operating cash flow (USD) 275M 303M 203M 178M 379M 142M 108M 119M 112M 80.3M
Purchases of property, plant and equipment (USD) -50.2M -60.2M -70.4M -66.1M -63.8M -68.6M -59.1M -58.5M -41.6M -34.3M
Change in receivables (cash effect) (USD) 3.36M -103,000 -10.5M 2.75M -11.2M 20.2M -11.4M -22.7M -7.76M 10.1M
Change in inventories (cash effect) (USD) 9.8M 7.54M -33.4M 18.4M -31.1M -95.3M 40.3M -13.2M 30.3M 11.9M
Change in payables (cash effect) (USD) 13.4M 6.83M -9.16M -7.18M 24.8M -13.3M 9.26M -10.1M -7.29M -9.11M
Dividends paid (cash effect) (USD) -78.4M -76.1M -80.6M -82.2M -78.4M -76.3M -77M -77.6M -11.9M -11.8M
Share buybacks (cash effect) (USD) -247M -71.7M -69.6M -825,000 -144M -80.4M -70M -13M 0.00 -20M
Interest paid (cash effect) (USD) -11.6M -18.4M -20.9M -17.9M -11.2M -8.6M -14.5M -33.3M -35.3M -16.7M
Income taxes paid (cash effect) (USD) -40.9M -78.1M -40.9M -97.9M -56.2M -96M -42.1M -32.4M -30.4M -40.8M
Share-based compensation (USD) 8.89M 19.3M 26.6M 9.91M 24.1M 23.2M 12.4M 15.6M 14.8M 24.1M
Operating cash flow before change in receivables (USD) 272M 303M 213M 175M 390M 121M 120M 141M 120M 70.2M
Free cash flow (OCF - PPE - intangibles) (USD) 225M 242M 132M 112M 315M 73M 49M 60.1M 70.2M 46M
Income detail
Research and development expense (USD) 24.3M 22M 23M 30.1M 23.3M 27.2M 23.3M 22.6M 13M 10.8M
↳ 5y CAGR +12.3% +8.1% +5.0% +9.8% +3.0% +2.3% +1.2% -0.4% -15.5% -14.3%
Total comprehensive income (USD) 130M 147M 108M 168M 212M 138M 92.2M -4.9M -171M 169M
Comprehensive income to owners (USD) 130M 147M 108M 168M 212M 138M 92.2M -4.9M -171M 169M
Reported Feb 27, 2017 Feb 16, 2018 May 1, 2019 May 7, 2020 Feb 11, 2021 Feb 16, 2022 Feb 16, 2023 Feb 15, 2024 Feb 14, 2025 Feb 13, 2026

Operating KPIs — quarters

KPI Sep 24 Jun 25 Sep 25 Jun 26
Customers 831,768 771,407 746,256 660,037
↳ YoY growth -10.3% -14.4%
Reported Nov 6, 2025 Sep 3, 2026 Nov 6, 2025 Sep 3, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Nu Skin Enterprises Reports Third Quarter Earnings Bull 0 Bear 4 Results

PROVO, Utah — Nov. 5, 2026 — Nu Skin Enterprises Inc. (NYSE: NUS) today announced third quarter revenue within its guidance range.

Executive Summary

Q3 2026 vs. Prior-year Quarter

Revenue

$311.0 million; (14.6)%

• (1.1)% FX impact or $(3.9) million

Earnings Per Share (EPS)

$(0.02) or $0.10 excluding certain charges compared to $0.34

Customers

609,469; (18)%

Paid Affiliates

116,449; (10)%

Sales Leaders

26,995; (13)%

“Third quarter revenue came in within our guidance range as we continued executing on our strategic priorities amid a challenging operating environment,” said Ryan Napierski, Nu Skin president and CEO. “During the quarter, we held our Nu Skin LIVE global convention in Japan, where we were excited to gather with 12,000 of our sales leaders and preview our next anti-aging offerings focused on women’s health. We continue to see adoption of our Prysm iO platform, including year-to-date growth in revenue from our flagship LifePak nutritional supplements.

PROVO, Utah — Aug. 10, 2026 — Nu Skin Enterprises Inc. (NYSE: NUS) today announced second quarter results.

Executive Summary

Q2 2026 vs. Prior-year Quarter

Revenue $320.1 million; (17.1)%·      (1.0)% FX impact or $(4.0) million
Earnings Per Share (EPS) $(5.14) or $0.20 excluding non-cash impairment and non-cash tax charges compared to $0.43
Customers 660,037; (14)%
Paid Affiliates 120,291; (8)%
Sales Leaders 26,998; (9)%

“We continue to make progress toward our long-term strategy with the continued rollout of Prysm iO and preparations for the formal launch of India,” said Ryan Napierski, Nu Skin president and CEO. “As these initiatives are taking hold, we are incorporating valuable learnings to strengthen our plans moving forward. At the same time, we are re-aligning our organizational resources to better position the business to drive sustainable, long-term value for our shareholders.”

Q2 2026 Year-over-year Operating Results               

Revenue $320.1 million compared to $386.1 million·      (1.0)% FX impact or $(4.0) million
Gross Margin 68.2% compared to 68.8%·      Nu Skin business was 77.7% compared to 77.5%
Selling Expenses 33.7% compared to 33.2%·      Nu Skin business was 39.8% compared to 40.0%
G&A Expenses 28.4% compared to 27.6%
Operating Margin (18.5)% or 6.1% excluding non-cash impairment charge compared to 8.0%
Interest Expense $3.3 million compared to $2.5 million
Other Income (Expense) $(0.5) million compared to $(0.8) million
Income Tax Rate (295.4)% or 36.6% excluding non-cash tax charge compared to 23.0%
EPS $(5.14) or $0.20 excluding non-cash impairment and non-cash tax charges compared to $0.43

**
Stockholder Value**

Dividend Payments $2.9 million
Stock Repurchases $0.0 million·      $137.3 million remaining in authorization

Q3 and Full-year 2026 Outlook

Q3 2026 Revenue $310 to $340 million; (15)% to (7)%·      Approximately (3) to (2)% FX impact
Q3 2026 EPS $0.00 to $0.09 or $0.10 to $0.20 on an adjusted basis
2026 Revenue $1.28 to $1.35 billion;  (14)% to (9)%·       Approximately (1)% FX impact
2026 EPS ($4.90) to ($4.73) or $0.70 to $0.90 on an adjusted basis

“We delivered adjusted earnings per share near the midpoint of our guidance, reflecting our ongoing focus on profitability and disciplined execution,” said Chelsea Lantz, interim chief financial officer. “Based on our first-half performance and outlook for the rest of the year, we are updating our annual guidance to revenue of $1.28 billion to $1.35 billion and adjusted earnings per share of $0.70 to $0.90. For the third quarter, we expect revenue between $310 million and $340 million, with adjusted earnings per share in the range of $0.10 to $0.20.”

Conference Call

The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com . A replay of the webcast will be available on the same page through Aug. 24, 2026.

About Nu Skin Enterprises Inc.

Nu Skin Enterprises Inc. (NYSE: NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company’s products help people look, feel and live their best with our newly introduced Prysm iO intelligent wellness platform, an award-winning line of beauty device systems and trusted brands in personal care and wellness products. Rhyz is the strategic investment arm of Nu Skin Enterprises, formed in 2018 consisting of synergistic consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.

Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s expectations regarding the company’s performance, growth, initiatives, shareholder value, Prysm launch and its timing, and India expansion; projections regarding revenue, expenses, margins, tax rates, earnings per share, foreign currency fluctuations, uses of cash, financial position and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “become,” “drive,” “project,” “outlook,” “guidance,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

·       any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a sustained basis;

·       risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;

·       economic conditions and events globally;

·       the company’s future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company’s products imported into the company’s markets, and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets;

·       competitive pressures in the company’s markets;

·       risk that epidemics or other crises, as well as any related disruptions, could negatively impact our business;

·       adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;

·       political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;

·       uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;

·       risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;

·       uncertainties regarding the future financial performance of the businesses the company has acquired;

·       risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies; and

·       regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements.

The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.

Earnings per share, operating margin, and income tax rate, each excluding impairment charges, tax charges, and/or other charges, also are non-GAAP financial measures.

·       Impairment charges and the tax charge incurred in the second quarter of 2026 are not part of the ongoing operations of our underlying business; and

·       The other charges incurred in connection with certain corporate actions, as described in the footnotes to the non-GAAP reconciliation tables below, are not part of our ongoing operations.

The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these items facilitates period-to-period comparisons of the company’s performance. Please see the reconciliations of these items to our earnings per share, gross margin, operating margin, income tax rate and revenue growth rate calculated under GAAP, below.

The following table sets forth revenue for the three-month periods ended June 30, 2026, and 2025 for each of our reportable segments (U.S. dollars in thousands):

Three Months Ended Constant-
June 30, Currency
2026 2025 Change Change
Nu Skin
Americas $ 59,763 $ 72,946 (18.1)% (15.8)%
Mainland China 45,956 53,224 (13.7)% (18.7)%
Southeast Asia/Pacific 43,257 50,834 (14.9)% (16.3)%
Japan 38,143 44,550 (14.4)% (5.5)%
Europe & Africa 32,317 37,328 (13.4)% (15.2)%
Hong Kong/Taiwan 26,074 27,527 (5.3)% (3.6)%
South Korea 25,620 34,068 (24.8)% (19.0)%
Nu Skin Other 79 427 (81.5)% (81.5)%
Total Nu Skin 271,209 320,904 (15.5)% (14.2)%
Rhyz
Manufacturing 46,369 60,400 (23.2)% (23.2)%
Rhyz Other 2,534 4,834 (47.6)% (47.6)%
Total Rhyz 48,903 65,234 (25.0)% (25.0)%
Total $ 320,112 $ 386,138 (17.1)% (16.1)%

The following table sets forth revenue for the six-month periods ended June 30, 2026, and 2025 for each of our reportable segments (U.S. dollars in thousands):

Six Months Ended Constant-
June 30, Currency
2026 2025 Change Change
Nu Skin
Americas $ 117,581 $ 142,004 (17.2)% (14.2)%
Mainland China 91,104 100,999 (9.8)% (14.6)%
Southeast Asia/Pacific 88,731 103,006 (13.9)% (16.5)%
Japan 77,882 87,315 (10.8)% (4.9)%
Europe & Africa 63,535 70,349 (9.7)% (15.0)%
Hong Kong/Taiwan 53,531 55,974 (4.4)% (4.8)%
South Korea 50,949 66,583 (23.5)% (20.2)%
Nu Skin Other (155) 956 (116.2)% (116.2)%
Total Nu Skin 543,158 627,186 (13.4)% (13.4)%
Rhyz
Manufacturing 91,294 115,690 (21.1)% (21.1)%
Rhyz Other 6,268 7,752 (19.1)% (19.1)%
Total Rhyz 97,562 123,442 (21.0)% (21.0)%
Total $ 640,720 $ 750,628 (14.6)% (14.6)%

The following tables provide information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods ended June 30, 2026 and 2025.

Three Months Ended
June 30,
2026 2025 Change
Customers
Americas 183,757 240,477 (24)%
Mainland China 103,891 117,325 (11)%
Southeast Asia/Pacific 69,354 72,814 (5)%
Japan 100,849 105,961 (5)%
Europe & Africa 111,332 126,146 (12)%
Hong Kong/Taiwan 36,549 41,371 (12)%
South Korea 54,305 67,313 (19)%
Total Customers 660,037 771,407 (14)%
Paid Affiliates
Americas 27,337 28,827 (5)%
Mainland China 18,736 19,399 (3)%
Southeast Asia/Pacific 17,677 21,092 (16)%
Japan 19,018 19,605 (3)%
Europe & Africa 13,307 15,320 (13)%
Hong Kong/Taiwan 9,390 9,570 (2)%
South Korea 14,826 16,986 (13)%
Total Paid Affiliates 120,291 130,799 (8)%
Sales Leaders
Americas 5,041 5,971 (16)%
Mainland China 5,899 5,790 2%
Southeast Asia/Pacific 3,631 4,126 (12)%
Japan 5,782 5,882 (2)%
Europe & Africa 2,216 2,695 (18)%
Hong Kong/Taiwan 1,858 2,063 (10)%
South Korea 2,571 3,066 (16)%
Total Sales Leaders 26,998 29,593 (9)%

·       “Customers” are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our salesforce who made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.

·       “Paid Affiliates” are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides Mainland China, we refer to members of our independent sales force as “Brand Affiliates” because their primary role is to promote our brand and products through their personal social networks.

·       “Sales Leaders” are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements as of the end of each month of the quarter.

NU SKIN ENTERPRISES, INC.

Consolidated Statements of Income (Unaudited)

(U.S. dollars in thousands, except per share amounts)

Three Months Ended Six Months Ended
June 30, June 30,
2026 2025 2026 2025
Revenue $ 320,112 $ 386,138 $ 640,720 $ 750,628
Cost of sales 101,787 120,405 207,932 237,934
Gross profit 218,325 265,733 432,788 512,694
Operating expenses:
Selling expenses 107,922 128,228 217,976 246,774
General and administrative expenses 90,847 106,725 189,391 219,929
Impairment expenses 78,875 - 80,714 25,114
Total operating expenses 277,644 234,953 488,081 491,817
Operating income (loss) (59,319) 30,780 (55,293) 20,877
Interest expense 3,322 2,526 7,572 5,809
Gain on sale of business - - - 176,162
Other income (expense), net (534) (843) 2,289 (29,218)
Income (loss) before provision for income taxes (63,175) 27,411 (60,576) 162,012
Provision for income taxes 186,623 6,292 187,386 33,378
Net income (loss) $ (249,798) $ 21,119 $ (247,962) $ 128,634
Net income (loss) per share (Note 7):
Basic $ (5.14) $ 0.43 $ (5.12) $ 2.59
Diluted $ (5.14) $ 0.43 $ (5.12) $ 2.59
Weighted-average common shares outstanding (000s):
Basic 48,596 49,441 48,400 49,601
Diluted 48,596 49,499 48,400 49,748

NU SKIN ENTERPRISES, INC.

Consolidated Balance Sheets (Unaudited)

(U.S. dollars in thousands)

June 30, December 31,
2026 2025
ASSETS
Current assets:
Cash and cash equivalents $ 189,643 $ 238,630
Current investments 1,743 1,211
Accounts receivable, net 48,902 39,544
Inventories, net 191,497 178,643
Prepaid expenses and other 76,364 89,670
Total current assets 508,149 547,698
Property and equipment, net 379,550 377,168
Operating lease right-of-use assets 65,442 74,021
Goodwill 4,750 83,625
Other intangible assets, net 37,884 42,614
Other assets 125,755 280,187
Total assets 1,121,530 1,405,313
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable $ 37,711 $ 26,183
Accrued expenses 198,636 217,551
Current portion of long-term debt 20,000 20,000
Total current liabilities 256,347 263,734
Operating lease liabilities 50,075 57,640
Long-term debt 193,664 204,187
Other liabilities 78,705 74,512
Total liabilities 578,791 600,073
Commitments and contingencies (Notes 6 and 12)
Stockholders’ equity:
Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued 91 91
Additional paid-in capital 612,412 635,994
Treasury stock, at cost – 41.9 million and 42.4 million shares (1,558,183) (1,575,059)
Accumulated other comprehensive loss (118,152) (116,105)
Retained earnings 1,606,571 1,860,319
Total stockholders' equity 542,739 805,240
Total liabilities and stockholders’ equity $ 1,121,530 $ 1,405,313
NU SKIN ENTERPRISES, INC. Reconciliation of Operating Margin Excluding Certain Charges to GAAP Operating Margin (in thousands, except for per share amounts)
Three months ended June 30, Six months ended June 30,
2026 2025 2026 2025
Operating Income $ (59,319) $ 30,780 $ (55,293) $ 20,877
Impact of inventory write-off - - 3,116 -
Impact of other charges(1) - - 2,643 7,966
Impact of impairment 78,875 - 80,714 25,114
Adjusted operating income $ 19,556 $ 30,780 $ 31,180 $ 53,957
Operating margin (18.5)% 8.0% (8.6)% 2.8%
Operating margin, excluding certain charges 6.1% 8.0% 4.9% 7.2%
Revenue $ 320,112 $ 386,138 $ 640,720 $ 750,628

(1) Other charges for the first quarter of 2026 consist of $1.0 million related to the wind down of the separate BeautyBio business and $1.6 million of other employee severance charges. Other charges for the first quarter of 2025 consist of expenses incurred in connection with the Mavely sale, including $2.7 million of transaction bonuses for certain employees and $5.2 million of equity compensation as a result of the vesting of the Mavely profits interest units.

NU SKIN ENTERPRISES, INC. Reconciliation of Effective Tax Rate Excluding Impact of Certain Charges to GAAP Effective Tax Rate (in thousands, except for per share amounts)
Three months ended June 30, Six months ended June 30,
2026 2025 2026 2025
Provision (benefit) for income taxes $ 186,623 $ 6,292 $ 187,386 $ 33,378
Impact of inventory write-off on provision for income taxes - - 1,065 -
Impact of other charges(1) on provision for income taxes - - 903 725
Impact of impairment on provision for income taxes (13,370) - (12,741) 5,433
Impact of gain on Mavely sale on provision for income taxes - - - (31,104)
Impact of gain on unrealized investment loss on provision for income taxes - - - 6,074
Impact of valuation allowance on deferred tax assets (167,505) - (167,505) -
Provision for income taxes, excluding impact of certain charges $ 5,748 $ 6,292 $ 9,108 $ 14,506
Income before provision for income taxes (63,175) 27,411 (60,576) 162,012
Impact of inventory write-off - - 3,116 -
Impact of other charges(1) - - 2,643 7,966
Impact of impairment expense: 78,875 - 80,714 25,114
Impact of gain on Mavely sale - - - (176,162)
Impact of unrealized investment loss - - - 28,077
Income before provision for income taxes, excluding impact certain charges $ 15,700 $ 27,411 $ 25,897 $ 47,007
Effective tax rate (295.4)% 23.0% (309.3)% 20.6%
Effective tax rate, excluding impact of certain charges 36.6% 23.0% 35.2% 30.9%
NU SKIN ENTERPRISES, INC. Reconciliation of Earnings Per Share Excluding Impact of Certain Charges to GAAP Earnings Per Share(in thousands, except for per share amounts)
Three months ended June 30, Six months ended June 30,
2026 2025 2026 2025
Net income $ (249,798) $ 21,119 $ (247,962) $ 128,634
Impact of Inventory write-off
Inventory write-off - - 3,116 -
Tax impact - - (1,065) -
Impact of other charges
Other charges - - 2,643 7,966
Tax impact - - (903) (725)
Impact of impairment
Impairment charges 78,875 - 80,714 25,114
Tax impact 13,370 - 12,741 (5,433)
Impact of Mavely sale
Mavely sale - - - (176,162)
Tax impact - - - 31,104
Impact of unrealized investment loss
Unrealized investment loss - - - 28,077
Tax impact - - - (6,074)
Impact of valuation allowance on deferred tax assets 167,505 - 167,505 -
Adjusted net income $ 9,952 $ 21,119 $ 16,789 $ 32,501
Diluted earnings per share $ (5.14) $ 0.43 $ (5.12) $ 2.59
Diluted earnings per share, excluding impact of certain charges $ 0.20 $ 0.43 $ 0.35 $ 0.65
Weighted-average common shares outstanding (000) 48,596 49,499 48,400 49,748
NU SKIN ENTERPRISES, INC. Reconciliation of Earnings Per Share Excluding Impact of Certain Charges to GAAP Earnings Per Share
Three months ended September 30, 2026 Year ended December 31, 2026
Low end High end Low end High end
Earnings Per Share $ 0.00 $ 0.09 $ (4.90) $ (4.73)
Impact of inventory write-off
Inventory write-off - - 0.06 0.06
Tax impact - - (0.02) (0.02)
Impact of other charges
Other charges(2) 0.10 0.10 0.15 0.15
Tax impact (0.02) (0.02) (0.04) (0.04)
Impact of impairment:
Impairment charges - - 1.67 1.67
Tax impact - - 0.26 0.26
Impact of valuation allowance on deferred tax assets 0.02 0.03 3.52 3.55
Adjusted EPS $ 0.10 $ 0.20 $ 0.70 $ 0.90

(2) We are currently anticipating other charges for the third quarter of 2026 of approximately $5 million in cash-based transition cost. Other charges for the first quarter of 2026 consist of $1.0 million related to the wind down of the separate BeautyBio business and $1.6 million of other employee severance charges.

# # #

Divider

Choose a Market

YouTube

LinkedIn

Instagram

Twitter

Facebook

< Back

Effective August 17, 2026, Justin Keisel, the Executive Vice President and President of Global Sales of Nu Skin Enterprises, Inc. (the “Company” or “we”), began a medical leave of absence. Chayce Clark, the Company’s Executive Vice President, Chief Operating Officer and Chief Legal Officer, will lead Mr. Keisel’s organization during his time away. We wish Mr. Keisel and his family all the best as he focuses on his health.

Prompts

Nu Skin Enterprises, Inc. (ticker NUS), listed in United States.

ETFs Holding Nu Skin Enterprises, Inc.

ETF Weight in ETF Shares Market value As of
MYLD 0.99% 64,849 $ 336.566K Jul 31, 2026
DWSH short -0.80% -13,128 $ -49.624K Nov 17, 2026
AFMC 0.25% 168,152 $ 660.837K Nov 16, 2026
AFSM 0.25% 92,498 $ 363.517K Nov 16, 2026
VFVA 0.07% 149,188 $ 699.692K Aug 31, 2026
SEIS 0.06% 67,487 $ 356.331K Jun 30, 2026
FEAC 0.05% 2,293 $ 12.107K Jun 30, 2026
VFQY 0.04% 44,560 $ 208.986K Aug 31, 2026
BSVO 0.04% 229,478 $ 870K Nov 18, 2026
AVUV 0.03% 2,613,455 $ 10.271M Nov 16, 2026
AVSC 0.01% 77,420 $ 304.261K Nov 16, 2026
DFSV 0.01% 539,144 $ 2.162M Nov 12, 2026
DFAT 0.00% 324,304 $ 1.3M Nov 12, 2026
DFAS 0.00% 122,350 $ 490.624K Nov 12, 2026
DFUS 0.00% 6,439 $ 25.82K Nov 12, 2026
AVUS 0.00% 38,038 $ 149.489K Nov 16, 2026
AVSU 0.00% 1,031 $ 4,051.83 Nov 16, 2026